Registry initiated to characterize vision loss associated with vigabatrin therapy

► A patient registry helps manage the risk of vigabatrin-induced vision loss. ► Registry participation is mandatory for vigabatrin prescribers and their patients. ► Analyses were conducted every 6 months for 2009-2010 and are now being completed annually. ► The registry requires risk-benefit assessments via vision monitoring. ► Kaplan-Meier analyses indicate more than 70% of patients had remained in the registry more than 6 months.